VBI Vaccines Inc. (NASDAQ:VBIV) Short Interest Up 145.4% in April

VBI Vaccines Inc. (NASDAQ:VBIV) was the recipient of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 709,500 shares, a growth of 145.4% from the March 31st total of 289,100 shares. Based on an average daily volume of 445,600 shares, the short-interest ratio is currently 1.6 days. Approximately 2.7% of the shares of the company are sold short.

VBI Vaccines Trading Down 4.2 %

NASDAQ VBIV traded down $0.03 on Friday, hitting $0.57. 187,246 shares of the company traded hands, compared to its average volume of 369,938. The business’s 50 day moving average price is $0.61 and its 200-day moving average price is $0.61. VBI Vaccines has a 52-week low of $0.45 and a 52-week high of $3.47. The company has a market capitalization of $16.32 million, a price-to-earnings ratio of -0.05 and a beta of 1.93.

Analyst Ratings Changes

Separately, StockNews.com began coverage on shares of VBI Vaccines in a report on Friday. They set a “sell” rating for the company.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.